Literature DB >> 20600493

Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza.

Jianping Lin1, Suryanarayan Somanathan, Soumitra Roy, Roberto Calcedo, James M Wilson.   

Abstract

We conducted a study to evaluate the protective efficacy in mice of vaccination with novel adenovirus vectors expressing an influenza A nucleoprotein (AdFluA-NP) based on isolates from non-human primates. In a previous study, we had observed that AdFluA-NP vectors can induce similar T cell responses in mice yet differ in ability to protect animals from lethal challenge with influenza A virus. To better define correlates of protection, we extended our study design to include additional novel AdFluA-NP vectors, and to evaluate cytotoxic T lymphocyte (CTL) responses in the spleens and lungs of immunized mice prior to virus challenge. As in our previous study, all vectors induced similar numbers of antigen-specific interferon gamma (IFNgamma) secreting T cells and memory T cells in the spleen 4 weeks post immunization, but differed in their ability to protect the animals from lethal infection. However, cytokine-secreting NP antigen-specific CTLs in the lungs of mice from immunization groups that survived lethal challenge showed greater proliferative ability and higher CD27 expression. In addition, NP antigen-specific peripheral blood lymphocytes from protected mice showed greater proliferative ability after ex vivo stimulation. Our results provide additional correlates of protection that should be considered when developing anti-influenza vaccines. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600493      PMCID: PMC3269910          DOI: 10.1016/j.vaccine.2010.06.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  CD27 is required for generation and long-term maintenance of T cell immunity.

Authors:  J Hendriks; L A Gravestein; K Tesselaar; R A van Lier; T N Schumacher; J Borst
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

2.  Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.

Authors:  Soumitra Roy; Guangping Gao; You Lu; Xiangyang Zhou; Martin Lock; Roberto Calcedo; James M Wilson
Journal:  Hum Gene Ther       Date:  2004-05       Impact factor: 5.695

3.  Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital.

Authors:  T W Hoskins; J R Davies; A J Smith; C L Miller; A Allchin
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

4.  Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

Authors:  Andrei N Varnavski; Katia Schlienger; Jeffrey M Bergelson; Guang-Ping Gao; James M Wilson
Journal:  Hum Gene Ther       Date:  2003-04-10       Impact factor: 5.695

5.  Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; V G Hemming; R L Horswood; P A Baron; R M Chanock
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

9.  Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.

Authors:  E D Kilbourne; B E Johansson; B Grajower
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

10.  CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool.

Authors:  Jenny Hendriks; Yanling Xiao; Jannie Borst
Journal:  J Exp Med       Date:  2003-10-27       Impact factor: 14.307

View more
  10 in total

1.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

2.  A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.

Authors:  Beth C Holbrook; Jong R Kim; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Ralph B D'Agostino; S Tyler Aycock; Mallinath B Hadimani; S Bruce King; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

3.  A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Authors:  Matthew D J Dicks; Alexandra J Spencer; Nick J Edwards; Göran Wadell; Kalifa Bojang; Sarah C Gilbert; Adrian V S Hill; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

4.  Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis.

Authors:  Marina Durward; Girish Radhakrishnan; Jerome Harms; Claire Bareiss; Diogo Magnani; Gary A Splitter
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 5.  Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines.

Authors:  Saranya Sridhar
Journal:  Front Immunol       Date:  2016-05-19       Impact factor: 7.561

6.  Virus replicon particle vaccines expressing nucleoprotein of influenza A virus mediate enhanced inflammatory responses in pigs.

Authors:  Meret E Ricklin; Sylvie Python; Nathalie J Vielle; Daniel Brechbühl; Beatrice Zumkehr; Horst Posthaus; Gert Zimmer; Nicolas Ruggli; Artur Summerfield
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

Review 7.  The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

Authors:  Brian J Ward; Stephane Pillet; Nathalie Charland; Sonia Trepanier; Julie Couillard; Nathalie Landry
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

8.  Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults.

Authors:  Stéphane Pillet; Julie Couillard; Sonia Trépanier; Jean-François Poulin; Bader Yassine-Diab; Bruno Guy; Brian J Ward; Nathalie Landry
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

Review 9.  Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines.

Authors:  Jianfeng Zhang
Journal:  Viruses       Date:  2012-11-01       Impact factor: 5.048

10.  Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial.

Authors:  Stéphane Pillet; Éric Aubin; Sonia Trépanier; Jean-François Poulin; Bader Yassine-Diab; Jan Ter Meulen; Brian J Ward; Nathalie Landry
Journal:  NPJ Vaccines       Date:  2018-01-23       Impact factor: 7.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.